Clinical Use Flashcards

1
Q

Intraarticular for chronic pain resulting from permanent joint changes

A

Dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

parenteral iron

A

(a) Patients in whom GI absorption is prevented by disease (b) Patient who cannot tolerate orally administered iron (c) Hemodialysis patients (Sodium ferric gluconate and iron sucrose)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Effective against P. falciparum

A

Halofantrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

immunosuppressant for transplantation

A

tacrolimus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Gametocidal

A

Primaquine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)

A

non-Hodgkin lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Primary and secondary prevention of thromboembolism in patients with nonvalvular atrial fibrillation

A

Dabigatran

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

used in pregnant patients with severe allergic reactions to heparin (e.g., HIT).

A

Fondaparinux and parenteral direct thrombin inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

(a) Patients in whom GI absorption is prevented by disease (b) Patient who cannot tolerate orally administered iron (c) Hemodialysis patients (Sodium ferric gluconate and iron sucrose)

A

parenteral iron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment and chemoprophylaxis of P. falciparum infections

A

“Atovaquone-proguanil aka Malarone”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

standard prophylactic drug in SE Asia (in combination with mefloquine)

A

Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

fludarabine

A

CLL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

circumvents the action of inhibitors of dihydrofolate reductase and potentiates the cytotoxic effects of 5- fluorouracil

A

Leucovorin (folinic acid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

DIC in patients where bleeding predominates

A

Fresh frozen plasma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

eluting stents - Approved for coronary artery disease

A

sirolimus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Pneumocystis jiroveci: Prophylaxis for first-episode infection and therapy for pneumonia

A

Trimethoprim/sulfamethoxazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

von Willebrand disease (types 1 or 2A)

A

DDAVP (desmopressin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Radical cure and terminal prophylaxis of infections with P. vivax and P. ovale; alternative chemoprophylaxis for all species

A

Primaquine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Infants usually receive an intramuscular injection at birth for VKDB prophylaxis

A

Phytonadione

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Treatment (with quinine) of infections with P. falciparum

A

Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Megaloblastic anemia

A

IM B12 and folic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Thromboprophylaxis in patients undergoing hip or knee replacement surgery

A

rivaroxaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

therapy of choice for many systemic fungal infections

A

Polyenes: Amphotericin B; followed by outpatient treatment with azoles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

blood schizontocide

A

Artemisinin Chloroquine Mefloquine Doxycycline Quinine and Quinidine Sulfadoxine-pyrimethamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Used only in combination with amphotericin B

A

flucytosine

26
Q

autoimmune disease, e.g., autoimmune hemolytic anemia

A

MPA or MMF; (Mycophenolic Acid and Mycophenolate Mofetil)

27
Q

Daclizumab and Basiliximab

A

Induction therapy for renal transplantation

28
Q

Adequate for minor bleeding episodes in patients with mild hemophilia A

A

DDAVP (desmopressin)

29
Q

used for prevention and acute treatment of VTE

A

heparin, LMWH, fondaparinux

30
Q

Treatment and secondary prevention of VTE (DVT or pulmonary embolism)

A

rivaroxaban

31
Q

patients with pernicious anemia or ileal disease

A

Cyanocobalamin (parenteral)

32
Q

Tretinoin

A

APL

33
Q

Drug of choice for treatment of P. falciparum-sensitive malaria & chemoprophylaxis of malaria

A

Chloroquine

34
Q

DIC in patients where thrombosis predominates

A

Heparin

35
Q

Immunosuppressants in patients with inflammatory bowel disease

A

azathioprine

36
Q

used in patients with HIT to prevent further thromboembolic complications

A

Lepirudin and argatroban

37
Q

Chemoprophylaxis and Treatment of infections with chloroquine‐resistant P. falciparum

A

Mefloquine

38
Q

von Willebrand disease (types 2B, 2M, and 3)

A

Plasma-derived vWF-containing products

39
Q

prophylactic administration when there is increased utilization such as in pregnancy and lactation

A

folate

40
Q

Iron poisoning if plasma concentration of iron > 3.5 mg/L

A

Deferoxamine

41
Q

Primary prophylaxis (regular replacement therapy) started at a young age before onset of joint bleeding in hemophilia A/B

A

Factor VIII/IX replacement Plasma-derived products; Recombinant factor VIII/IX

42
Q

In patients with pernicious anemia high doses are used since it is absorbed via passive diffusion

A

Cyanocobalamin (oral)

43
Q

High doses can control bleeding in acute bleeding episodes

A

Factor VIII/IX replacement Plasma-derived products; Recombinant factor VIII/IX

44
Q

ABVD - doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine

A

Hodgkin lymphoma

45
Q

First line therapies for P. falciparum malaria, especially cerebral malaria

A

Quinine and Quinidine

46
Q

Treatment of acute bleeding episodes in patients with low inhibitor titer

A

Aminocaproic acid; Tranexamic acid

47
Q

Therapy for meningitis caused by Cryptococcus neoformans

A

Amphotericin B + flucytosine followed by fluconazole

48
Q

Active against hepatic-stage schizonts”

A

Primaquine “Atovaquone-proguanil aka Malarone”

49
Q

Vitamin K deficiency

A

Phytonadione

50
Q

imatinib

A

CML

51
Q

Treatment of acute bleeding episodes in patients with high inhibitor titer

A

Prothrombin complex concentrate (PCC) and activated PCC (aPCC) OR Recombinant factor VIIa

52
Q

Therapy for encephalitis cause by Toxoplasma gondii

A

Pyrimethamine/sulfadiazine

53
Q

Treatment of infections with some chloroquine‐resistant P. falciparum; could be combined with artesunate; preventive therapy in endemic areas

A

Sulfadoxine-pyrimethamine

54
Q

preferred for prevention and treatment of VTE in pregnancy

A

Low-molecular weight heparins (e.g., enoxaparin)

55
Q

Available as a fixed dose combination with Artemether – 1st line therapy for uncomplicated malaria in most of Africa

A

Lumefantrine

56
Q

Prophylaxis for first episode Toxoplasma gondii

A

Trimethoprim/sulfamethoxazole

57
Q

Prevention of graft versus host disease

A

Mtx

58
Q

Secondary prophylaxis: Cryptococcus neoformans

A

fluconazole

59
Q

active against HBV and HIV

A

Lamivudine (nucleoside analog of cytosine), Emtricitabine (fluorinated analog of lamivudine), Tenofovir (nucleotide analog of adenosine)

60
Q

Prevention and treatment of VTE: In patients with atrial fibrillation and a presumed cardiac source of embolism, the antithrombotic agent of first choice for primary and secondary prevention of ischemic stroke

A

warfarin